Balabanov P

Office for Neurological and Psychiatric Disorders, European Medicines Agency, 1083 HS Amsterdam, Netherlands.

2 papers

ArticlePsychedelics

Applying the EU Regulatory Framework to Determine the Benefit-Risk Profile of Psychedelics.

Browne K, Bałkowiec-Iskra E, Elferink A +10

Europe PMC2025
ArticlePsilocybin

A review of psychedelics trials completed in depression, informed by European regulatory perspectives.

Silva F, Butlen-Ducuing F, Guizzaro L +1

Europe PMC2025